Biologics Delay Progression of Crohn's Disease, but Not Early Surgery, in Children

Background & Aims: Up to 30% of patients with Crohn's disease (CD) require surgery within the first 5 years from diagnosis. We investigated the recent risk of bowel surgery in an inception cohort of pediatric patients with CD and whether early use of biologics (tumor necrosis factor antagonists) alters later disease course. Methods: We collected data from the Pediatric Inflammatory Bowel Disease Collaborative Research Group registry on 1442 children (age, ó16 y) diagnosed with CD from January 2002 through December 2014. Data were collected at diagnosis, 30 days following diagnosis, and then quarterly and during hospitalizations for up to 12 years. Our primary aim was to determine the 10-year risk for surgery in children with CD. Our secondary aim was to determine whether early use of biologics (<3 mo of diagnosis) affected risk of disease progression. Results: The 10-year risk of first bowel surgery was 26%. The 5-year risk of bowel surgery did not change from 2002 through 2014, and remained between 13% and 14%. Most surgeries occurred within 3 years from diagnosis. The only predictor of surgery was disease behavior at diagnosis. CD with inflammatory behavior had the lowest risk of surgery compared to stricturing disease, penetrating disease, or both. We associated slowing of disease progression to stricturing or penetrating disease (but not surgery) with early use of biologics, but this effect only became evident after 5 years of disease. Our results indicate that biologics slow disease progression over time (hazard ratio, 0.85; 95% CI, 0.76?0.95). Conclusions: In an analysis of data from a registry of pediatric patients with CD, we found that among those with significant and progressing disease at or shortly after presentation, early surgery is difficult to prevent, even with early use of biologics. Early use of biologics (<3 mo of diagnosis) can delay later disease progression to stricturing and/or penetrating disease, but this affect could become evident only years after initial management decisions are made

Fourth report on chicken genes and chromosomes 2022

The chicken continues to hold its position as a leading model organism within many areas of research, as well as a being major source of protein for human consumption. The First Report on Chicken Genes and Chromosomes [Schmid et al., 2000], which was published in 2000, was the brainchild of the late, and sadly missed, Prof Michael Schmid of the University of Würzburg. It was a publication bringing together updates on the latest research and resources in chicken genomics and cytogenetics. The success of this First report led to the subsequent publication of the Second [Schmid et al., 2005] and Third [Schmid et al., 2015] reports proving popular references for the research community. It is now our pleasure to be able to introduce publication of the Fourth report. Being seven years since the last report, this publication captures the many advances that have taken place during that time. This includes presentation of the detailed genomic resources that are now available, largely due to increasing capabilities of sequencing technologies and which herald the pangenomic age, allowing for a much richer and more complete knowledge of the avian genome. Ongoing cytogenetic work also allows for examination of chromosomes, specific elements within chromosomes and the evolutionary history and comparison of karyotypes. We also examine chicken research efforts with a much more ‘global’ outlook with a greater impact on food security and the impact of climate change, and highlight the efforts of international consortia, such as the Chicken Diversity Consortium. We dedicate this Report to Michael